<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107555">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01875263</url>
  </required_header>
  <id_info>
    <org_study_id>FPS-COL-2013-06</org_study_id>
    <secondary_id>2013-000511-24</secondary_id>
    <nct_id>NCT01875263</nct_id>
  </id_info>
  <brief_title>Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.</brief_title>
  <official_title>Efficacy of a Short-term Sequential Therapy Versus Intravenous Standard Treatment for Patients With Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the efficacy of a sequential regimen of 14 days in patients with catheter-related
      bacteremia by S. aureus methicillin-susceptible, selected based on a pre-established
      clinical and microbiological criteria.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Reduce the rate of late complications of catheter-related bacteremia by S. aureus methicillin sensitive below 2%.</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reducing hospital stay associated with the treatment of uncomplicated bacteremia MS S. aureus.</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduce the transesophagic echocardiography</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Increase efficiency in the management of patients with bacteremia due to MS S. aureus, reducing the number of echocardiographic evidence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Staphylococcus</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cloxacillin 2g / 4 hours iv, 5 days followed levofloxacin 500 mg po / 24, 9 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cloxacillin 2g / 4 hrs iv 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cloxacilin</intervention_name>
    <description>2g/4 hours i.v., 5 days</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cloxacillin</intervention_name>
    <description>2g/4h 14 days   Standard therapy</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>500 mg v.o./24h, 9 days</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients ≥ 18 years with a minimum weight of 40 kg.

          -  Microbiological Isolation of S. aureus susceptible to meticillin.

          -  Start antibiotic treatment with drugs active against S. aureus within 72 hours   from
             the onset of clinical manifestations.

          -  Women of childbearing potential, negative pregnancy test negative serum or urine or
             statement is not pregnant.

          -  Prescription prior treatment must be independent and decoupled patient inclusion in
             the study, corresponding exclusively to clinical practice.

        Exclusion Criteria:

          -  Polymicrobial bacteremia.

          -  Neutropenic patients.

          -  Patients addicted to intravenous drugs.

          -  Patients with malignancies with expected survival less than 6 months.

          -  Severe allergy to beta-lactams or fluoroquinolones.

          -  Creatinine clearance &lt;20ml/min.

          -  Need for hemodialysis, peritoneal dialysis or plasmapheresis.

          -  Clinical signs of deep infection in the first five days of treatment  (mucocutaneous
             lesions suggestive of IE, embolic events, suppurative  thrombophlebitis.

          -  Predictors of bacteremia complicated:

          -  Positive blood cultures for 48-96 hours of starting treatment antistaphylococcal

          -  Clinical Instability

          -  Signs of sepsis or persistent fever at day 4 of treatment

          -  Existence of valvular or vascular prosthetic joints, vascular catheter not  removed
             within three days

          -  Heart disease predisposing to endocarditis.

          -  Patients presenting diagnosis concomitant infection by another organism.

          -  Pregnant or breast-feeding.

          -  Patients with epilepsy.

          -  Patients with a history of tendon disorders related to fluoroquinolone
             administration.

          -  Not have signed informed consent.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>José Manuel Lomas Cabezas</last_name>
    <email>jlomascabezas@yahoo.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mª del Mar Benjumea Vargas</last_name>
    <phone>955 040 460</phone>
    <email>gestionensayosclinicos.fps@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Jerez de la Frontera</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvador Pérez Cortés</last_name>
      <email>tito.pc@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Salvador Pérez Cortés</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <state>Málaga</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier de la Torre Lima</last_name>
      <email>jtorrel@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Javier De la Torre Lima</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clara Natera Kindelán</last_name>
      <email>clrntr@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Clara Natera Kindelán</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Hidalgo Tenorio</last_name>
      <email>chidalgo72@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Carmen Hidalgo Tenorio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Huelva</name>
      <address>
        <city>Huelva</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Manuel Lomas Cabeza</last_name>
      <email>jlomascabezas@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>José Manuel Lomas Cabeza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Can Misses</name>
      <address>
        <city>Ibiza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Antonio González Nieto</last_name>
      <email>josea_gnieto@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>José Antonio González Nieto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Antequera</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco Jarilla Fernández</last_name>
      <email>fcojarilla@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Francisco Jarilla Fernández</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Nuño Álvarez</last_name>
      <email>enrique.nuno@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Enrique Nuño Álvarez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Comarcal Carlos Haya</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio José Plata Ciézar</last_name>
      <email>nonispc@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Antonio José Plata Ciézar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>César Arístides de Alarcón González</last_name>
      <email>caristo.alarcon.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>César Arístides de Alarcón González</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Valme</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva María León Jiménez</last_name>
      <email>evam.leon.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Eva María León Jiménez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>June 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>catheter-related bacteremia, SAMS</keyword>
  <keyword>catheter related bacteremia</keyword>
  <keyword>susceptible</keyword>
  <keyword>aureus meticillin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cloxacillin</mesh_term>
    <mesh_term>Methicillin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
